Xtant Medical (XTNT) to Post Quarterly Earnings on Monday

Xtant Medical (NYSEAMERICAN:XTNT) is expected to post its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Xtant Medical to announce earnings of ($0.02) per share and revenue of $24.8760 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:30 AM ET.

Xtant Medical (NYSEAMERICAN:XTNT) last announced its quarterly earnings results on Wednesday, May 13th. The medical device company reported ($0.02) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.02). The company had revenue of $20.88 million during the quarter, compared to the consensus estimate of $20.16 million. Xtant Medical had a return on equity of 3.68% and a net margin of 1.50%.

Xtant Medical Trading Down 0.6%

NYSEAMERICAN:XTNT opened at $0.43 on Friday. The stock has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.52. The stock has a market cap of $60.28 million, a P/E ratio of 43.02 and a beta of -0.16. Xtant Medical has a 1 year low of $0.39 and a 1 year high of $0.95. The company has a debt-to-equity ratio of 0.17, a quick ratio of 1.64 and a current ratio of 3.34.

Wall Street Analyst Weigh In

Separately, BTIG Research restated a “buy” rating and set a $1.00 target price on shares of Xtant Medical in a research note on Wednesday, May 13th. Two equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $1.00.

Institutional Investors Weigh In On Xtant Medical

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in Xtant Medical in the second quarter valued at $26,000. Wiregrass Investment Management LLC purchased a new position in shares of Xtant Medical during the fourth quarter worth about $81,000. Mink Brook Asset Management LLC grew its holdings in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock worth $81,000 after purchasing an additional 60,997 shares during the last quarter. Renaissance Technologies LLC increased its position in shares of Xtant Medical by 28.8% during the fourth quarter. Renaissance Technologies LLC now owns 919,860 shares of the medical device company’s stock worth $721,000 after purchasing an additional 205,945 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in shares of Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares in the last quarter. 69.33% of the stock is currently owned by institutional investors and hedge funds.

About Xtant Medical

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.